What’s the Problem?
According to an FDA Recall Notice dated 8/20/20, this recall affects 1 lot of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg, 1000 count bottles and 1 lot of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 count bottles. The metformin was produced by Beximco Pharmaceuticals Limited, Dhaka, Bangladesh in June 2019, for U.S. distribution by Bayshore Pharmaceuticals, LLC, of Short Hills, New Jersey.
This recall was issued after FDA testing found NDMA levels in excess of the Acceptable Daily Intake Limit (ADI) in lot number 18657 of Bayshore Pharmaceuticals’ Metformin Hydrochloride Extended-Release Tablets, USP 750 mg.
FDA has classified NDMA as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. Animal studies have linked NDMA to liver, lung, kidney and colorectal cancer.
Consumers who were prescribed any recalled metformin should talk to their doctor for advise regarding an alternative treatment. Do not stop taking metformin without consulting your physician, as doing so could result in adverse medical consequences.
Do I Have a Bayshore Metformin Recall Class Action Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Bayshore Metformin Recall Lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.
If you or a loved one was injured by metformin, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.